Fc receptor‐like 1–5 molecules are similarly expressed in progressive and indolent clinical subtypes of B‐cell chronic lymphocytic leukemia
Tohid Kazemi(Tehran University of Medical Sciences), Fazel Shokri(Academic Center for Education, Culture and Research), Hossein Asgarian‐Omran(University of Tehran), Seyed Mohsen Razavi(Firoozgar General Hospital), Mohammad Hojjat‐Farsangi(Karolinska University Hospital), Mahmood Jeddi‐Tehrani(Academic Center for Education, Culture and Research), Hodjatallah Rabbani(Biotechnology Research Center), Mahdi Shabani(Shiraz University of Medical Sciences), Ramazan Ali Sharifian(University of Tehran), Ali Memarian(Tehran University of Medical Sciences)
Cited by 41
Related Papers
Nanoparticles and targeted drug delivery in cancer therapy
|Immunology Letters|2017|507
The significant role of interleukin-6 and its signaling pathway in the immunopathogenesis and treatment of breast cancer
|Biomedicine & Pharmacotherapy|2018|312
Small-Molecule Inhibitors of the Receptor Tyrosine Kinases: Promising Tools for Targeted Cancer Therapies
|International Journal of Molecular Sciences|2014|202
CDK1 in Breast Cancer: Implications for Theranostic Potential
|Anti-Cancer Agents in Medicinal Chemistry|2020|169
Adenosine and adenosine receptors in the immunopathogenesis and treatment of cancer
|Journal of Cellular Physiology|2017|150